个人中心 - 老虎社区

LiliMe

IP属地：未知

帖子 · 12帖子 · 12
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- LiliMeLiliMe
  ·2021-12-29
  👌
  非常抱歉，此主贴已删除
  1,343 评论
  4
  分享
  举报
- LiliMeLiliMe
  ·2021-12-19
  Interesting
  非常抱歉，此主贴已删除
  1,644 1
  5
  分享
  举报
- LiliMeLiliMe
  ·2021-12-10
  👍
  Singapore Stock Market Tipped To Head South Again On Friday
  The Singapore stock market bounced higher again on Thursday, one session after halting the three-day
  Singapore Stock Market Tipped To Head South Again On Friday
  1,305 评论
  3
  分享
  举报
- LiliMeLiliMe
  ·2021-12-10
  👍
  非常抱歉，此主贴已删除
  1,342 评论
  2
  分享
  举报
- LiliMeLiliMe
  ·2021-12-03
  Ok
  5 Stocks To Watch For December 3, 2021
  Some of the stocks that may grab investor focus today are: Wall Street expects Big Lots, Inc. (NYSE: BIG) to report a quarterly loss at $0.16 per share on revenue of $1.32 billion before the opening bell. Big Lots shares fell 5% to $41.45 in after-hours trading.
  5 Stocks To Watch For December 3, 2021
  2,056 1
  5
  分享
  举报
- LiliMeLiliMe
  ·2021-12-02
  Thanks
  10 Biggest Price Target Changes For Wednesday
  Morgan Stanley boosted Zscaler, Inc. price target from $275 to $330. Zscaler shares rose 7.1% to $37
  10 Biggest Price Target Changes For Wednesday
  1,315 评论
  点赞
  分享
  举报
- LiliMeLiliMe
  ·2021-12-02
  Thanks
  10 Biggest Price Target Changes For Wednesday
  Morgan Stanley boosted Zscaler, Inc. price target from $275 to $330. Zscaler shares rose 7.1% to $37
  10 Biggest Price Target Changes For Wednesday
  1,353 评论
  点赞
  分享
  举报
- LiliMeLiliMe
  ·2021-12-01
  👍
  5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market
  Here are the stocks to watch as the omicron variant gives rise to a new vaccine race
  5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market
  1,228 评论
  1
  分享
  举报
- LiliMeLiliMe
  ·2021-12-01
  👍
  Gold and silver stocks jumped in morning trading
  Gold and silver stocks jumped in morning trading.
  Gold and silver stocks jumped in morning trading
  1,391 评论
  1
  分享
  举报
- LiliMeLiliMe
  ·2021-11-29
  👍
  Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week
  The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday
  Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week
  1,706 评论
  5
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4099622722860440","uuid":"4099622722860440","gmtCreate":1636542016438,"gmtModify":1636545120034,"name":"LiliMe","pinyin":"lilime","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/4202d921353cc8edc625e395870b44a6","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":34,"tweetSize":12,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.53%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":696418072,"gmtCreate":1640745844616,"gmtModify":1640745844757,"author":{"id":"4099622722860440","authorId":"4099622722860440","name":"LiliMe","avatar":"https://static.tigerbbs.com/4202d921353cc8edc625e395870b44a6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099622722860440","authorIdStr":"4099622722860440"},"themes":[],"htmlText":"👌","listText":"👌","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696418072","repostId":"1186633322","repostType":4,"isVote":1,"tweetType":1,"viewCount":1343,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699731988,"gmtCreate":1639890328741,"gmtModify":1639890328871,"author":{"id":"4099622722860440","authorId":"4099622722860440","name":"LiliMe","avatar":"https://static.tigerbbs.com/4202d921353cc8edc625e395870b44a6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099622722860440","authorIdStr":"4099622722860440"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699731988","repostId":"2192035909","repostType":4,"isVote":1,"tweetType":1,"viewCount":1644,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605979131,"gmtCreate":1639106306823,"gmtModify":1639106602213,"author":{"id":"4099622722860440","authorId":"4099622722860440","name":"LiliMe","avatar":"https://static.tigerbbs.com/4202d921353cc8edc625e395870b44a6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099622722860440","authorIdStr":"4099622722860440"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605979131","repostId":"1144028780","repostType":4,"repost":{"id":"1144028780","kind":"news","pubTimestamp":1639094962,"share":"https://www.laohu8.com/m/news/1144028780?lang=&edition=full","pubTime":"2021-12-10 08:09","market":"sg","language":"en","title":"Singapore Stock Market Tipped To Head South Again On Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1144028780","media":"RTTNews","summary":"The Singapore stock market bounced higher again on Thursday, one session after halting the three-day","content":"<p></p>\n<p></p>\n<p>The Singapore stock market bounced higher again on Thursday, one session after halting the three-day winning streak in which it had collected almost 45 points or 1.4 percent. The Straits Times Index now sits just above the 3,140-point plateau although it's likely to see renewed selling pressure on Friday.</p>\n<p></p>\n<p>The global forecast for the Asian markets is negative, with profit taking expected particularly among the oil and technology stocks. The European and U.S. markets finished lower and the Asian markets figure to open in similar fashion.</p>\n<p></p>\n<p>The STI finished modestly higher on Thursday following gains from the industrials and a mixed picture from the financial shares.</p>\n<p></p>\n<p>For the day, the index gained 12.68 points or 0.41 percent to finish at 3,142.45 after trading between 3,134.40 and 3,152.34. Volume was 1.3 billion shares worth 867.3 million Singapore dollars. There were 280 gainers and 156 decliners.</p>\n<p></p>\n<p>Among the actives, City Developments soared 1.30 percent, while Comfort DelGro advanced 0.71 percent, Dairy Farm International dropped 0.99 percent, DBS Group dipped 0.13 percent, Genting Singapore added 0.64 percent, Keppel Corp was up 0.38 percent, Mapletree Commercial Trust rallied 0.98 percent, Mapletree Logistics Trust gained 0.53 percent, Oversea-Chinese Banking Corporation sank 0.44 percent, SATS accelerated 1.03 percent, SembCorp Industries rose 0.50 percent, Singapore Airlines spiked 1.20 percent, Singapore Exchange perked 0.75 percent, Singapore Press Holdings jumped 0.86 percent, Singapore Technologies Engineering climbed 0.80 percent, United Overseas Bank collected 0.19 percent, Wilmar International surged 1.44 percent, Yangzijiang Shipbuilding gathered 0.77 percent and CapitaLand Integrated Commercial Trust, Ascendas REIT, SingTel and Thai Beverage were unchanged.</p>\n<p></p>\n<p>The lead from Wall Street is soft as the major averages opened lower on Thursday. The Dow moved into the green for a time before ending flat, while the NASDAQ and S&amp;P 500 finished solidly in the red.</p>\n<p></p>\n<p>The Dow eased 0.06 points to finish at 25,754.69, while the NASDAQ tumbled 269.62 points or 1.71 percent to close at 15,517.37 and the S&amp;P 500 dropped 33.76 points or 0.72 percent to end at 4,667.45.</p>\n<p></p>\n<p>The pullback on Wall Street came as traders cashed in on the recent strength in the markets, which saw stocks recover strongly from the post-Thanksgiving sell-off triggered by the detection of the Omicron variant of the coronavirus.</p>\n<p></p>\n<p>With concerns about the impact of the Omicron variant easing, traders are now looking ahead to next week's Federal Reserve's monetary policy announcement. Reports suggest the Fed could decide to double the pace of tapering its asset purchase program to $30 billion per month.</p>\n<p></p>\n<p>In economic news, the Labor Department said first-time jobless claims pulled back by much more than expected last week.</p>\n<p></p>\n<p>Crude oil settled lower Thursday amid concerns about the outlook for energy demand following several countries imposing fresh restrictions on movements to curb the spread of Omicron. West Texas Intermediate Crude oil futures for January sank $1.42 or 2 percent at $70.94 a barrel.</p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stock Market Tipped To Head South Again On Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stock Market Tipped To Head South Again On Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 08:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.rttnews.com/3248262/singapore-stock-market-tipped-to-head-south-again-on-friday.aspx?type=acom><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market bounced higher again on Thursday, one session after halting the three-day winning streak in which it had collected almost 45 points or 1.4 percent. The Straits Times Index ...</p>\n\n<a href=\"https://www.rttnews.com/3248262/singapore-stock-market-tipped-to-head-south-again-on-friday.aspx?type=acom\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3248262/singapore-stock-market-tipped-to-head-south-again-on-friday.aspx?type=acom","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144028780","content_text":"The Singapore stock market bounced higher again on Thursday, one session after halting the three-day winning streak in which it had collected almost 45 points or 1.4 percent. The Straits Times Index now sits just above the 3,140-point plateau although it's likely to see renewed selling pressure on Friday.\n\nThe global forecast for the Asian markets is negative, with profit taking expected particularly among the oil and technology stocks. The European and U.S. markets finished lower and the Asian markets figure to open in similar fashion.\n\nThe STI finished modestly higher on Thursday following gains from the industrials and a mixed picture from the financial shares.\n\nFor the day, the index gained 12.68 points or 0.41 percent to finish at 3,142.45 after trading between 3,134.40 and 3,152.34. Volume was 1.3 billion shares worth 867.3 million Singapore dollars. There were 280 gainers and 156 decliners.\n\nAmong the actives, City Developments soared 1.30 percent, while Comfort DelGro advanced 0.71 percent, Dairy Farm International dropped 0.99 percent, DBS Group dipped 0.13 percent, Genting Singapore added 0.64 percent, Keppel Corp was up 0.38 percent, Mapletree Commercial Trust rallied 0.98 percent, Mapletree Logistics Trust gained 0.53 percent, Oversea-Chinese Banking Corporation sank 0.44 percent, SATS accelerated 1.03 percent, SembCorp Industries rose 0.50 percent, Singapore Airlines spiked 1.20 percent, Singapore Exchange perked 0.75 percent, Singapore Press Holdings jumped 0.86 percent, Singapore Technologies Engineering climbed 0.80 percent, United Overseas Bank collected 0.19 percent, Wilmar International surged 1.44 percent, Yangzijiang Shipbuilding gathered 0.77 percent and CapitaLand Integrated Commercial Trust, Ascendas REIT, SingTel and Thai Beverage were unchanged.\n\nThe lead from Wall Street is soft as the major averages opened lower on Thursday. The Dow moved into the green for a time before ending flat, while the NASDAQ and S&P 500 finished solidly in the red.\n\nThe Dow eased 0.06 points to finish at 25,754.69, while the NASDAQ tumbled 269.62 points or 1.71 percent to close at 15,517.37 and the S&P 500 dropped 33.76 points or 0.72 percent to end at 4,667.45.\n\nThe pullback on Wall Street came as traders cashed in on the recent strength in the markets, which saw stocks recover strongly from the post-Thanksgiving sell-off triggered by the detection of the Omicron variant of the coronavirus.\n\nWith concerns about the impact of the Omicron variant easing, traders are now looking ahead to next week's Federal Reserve's monetary policy announcement. Reports suggest the Fed could decide to double the pace of tapering its asset purchase program to $30 billion per month.\n\nIn economic news, the Labor Department said first-time jobless claims pulled back by much more than expected last week.\n\nCrude oil settled lower Thursday amid concerns about the outlook for energy demand following several countries imposing fresh restrictions on movements to curb the spread of Omicron. West Texas Intermediate Crude oil futures for January sank $1.42 or 2 percent at $70.94 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1305,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605979970,"gmtCreate":1639106274084,"gmtModify":1639106601602,"author":{"id":"4099622722860440","authorId":"4099622722860440","name":"LiliMe","avatar":"https://static.tigerbbs.com/4202d921353cc8edc625e395870b44a6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099622722860440","authorIdStr":"4099622722860440"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605979970","repostId":"1120676537","repostType":4,"isVote":1,"tweetType":1,"viewCount":1342,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601261439,"gmtCreate":1638536050441,"gmtModify":1638536050529,"author":{"id":"4099622722860440","authorId":"4099622722860440","name":"LiliMe","avatar":"https://static.tigerbbs.com/4202d921353cc8edc625e395870b44a6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099622722860440","authorIdStr":"4099622722860440"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601261439","repostId":"2188540330","repostType":4,"repost":{"id":"2188540330","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1638524158,"share":"https://www.laohu8.com/m/news/2188540330?lang=&edition=full","pubTime":"2021-12-03 17:35","market":"us","language":"en","title":"5 Stocks To Watch For December 3, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2188540330","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\tWall Street expects  Big Lots, Inc.  (NYSE: BIG) to report a quarterly loss at $0.16 per share on revenue of $1.32 billion before the opening bell. Big Lots shares fell 5% to $41.45 in after-hours trading.\n","content":"<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects&nbsp;<b>Big Lots, Inc.</b>&nbsp;(NYSE:BIG) to report a quarterly loss at $0.16 per share on revenue of $1.32 billion before the opening bell. Big Lots shares fell 5% to $41.45 in after-hours trading&nbsp;Thursday.</li>\n <li><b>DiDi Global Inc.</b>&nbsp;(NYSE:DIDI) said that its board of directors had authorized the company to initiate procedures to delist the company’s shares from the New York Stock Exchange. The company, however, announced plans to pursue a listing of its class A ordinary shares on the Main Board of the Hong Kong Stock Exchange. DiDi Global shares jumped 9.5% to $8.54 in premarket trading&nbsp;Friday.</li>\n <li>Analysts are expecting&nbsp;<b>Hibbett, Inc.</b>&nbsp;(NASDAQ:HIBB) to have earned $1.57 per share on revenue of $360.63 million for the latest quarter. The company will release earnings before the markets open. Hibbett shares rose 0.3% to $72.35 in after-hours trading&nbsp;Thursday.</li>\n</ul>\n<ul>\n <li><b>Tesla Inc</b> (NASDAQ:TSLA) Elon Musk sold another 934,091 shares worth around $1.01 billion in order to fulfill his tax obligations, as per filings made with the U.S. Securities And Exchange Commission Thursday. Musk also exercised options to purchase 2.1 million shares of the automaker at $6.24, as per one of the filings. In late November, the company’s CEO had sold $1 billion worth of Tesla shares. Tesla shares rose 0.3% to $1,088 in premarket tradingFriday.</li>\n <li><b>Ulta Beauty, Inc.</b> (NASDAQ:ULTA) reported better-than-expected results for its third quarter and raised its FY21 forecast. Ulta Beauty shares climbed 5.2% to $403.50 in the after-hours trading Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For December 3, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For December 3, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-03 17:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects&nbsp;<b>Big Lots, Inc.</b>&nbsp;(NYSE:BIG) to report a quarterly loss at $0.16 per share on revenue of $1.32 billion before the opening bell. Big Lots shares fell 5% to $41.45 in after-hours trading&nbsp;Thursday.</li>\n <li><b>DiDi Global Inc.</b>&nbsp;(NYSE:DIDI) said that its board of directors had authorized the company to initiate procedures to delist the company’s shares from the New York Stock Exchange. The company, however, announced plans to pursue a listing of its class A ordinary shares on the Main Board of the Hong Kong Stock Exchange. DiDi Global shares jumped 9.5% to $8.54 in premarket trading&nbsp;Friday.</li>\n <li>Analysts are expecting&nbsp;<b>Hibbett, Inc.</b>&nbsp;(NASDAQ:HIBB) to have earned $1.57 per share on revenue of $360.63 million for the latest quarter. The company will release earnings before the markets open. Hibbett shares rose 0.3% to $72.35 in after-hours trading&nbsp;Thursday.</li>\n</ul>\n<ul>\n <li><b>Tesla Inc</b> (NASDAQ:TSLA) Elon Musk sold another 934,091 shares worth around $1.01 billion in order to fulfill his tax obligations, as per filings made with the U.S. Securities And Exchange Commission Thursday. Musk also exercised options to purchase 2.1 million shares of the automaker at $6.24, as per one of the filings. In late November, the company’s CEO had sold $1 billion worth of Tesla shares. Tesla shares rose 0.3% to $1,088 in premarket tradingFriday.</li>\n <li><b>Ulta Beauty, Inc.</b> (NASDAQ:ULTA) reported better-than-expected results for its third quarter and raised its FY21 forecast. Ulta Beauty shares climbed 5.2% to $403.50 in the after-hours trading Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CEO":"中海油","BK4526":"热门中概股","BK4539":"次新股","BK4200":"专卖店","BK4505":"高瓴资本持仓","HIBB":"希贝特体育","ULTA":"Ulta美容","TSLA":"特斯拉","BK4114":"综合货品商店","BK4022":"陆运","BK4535":"淡马锡持仓","BK4561":"索罗斯持仓","DIDI":"滴滴(已退市)"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188540330","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Big Lots, Inc. (NYSE:BIG) to report a quarterly loss at $0.16 per share on revenue of $1.32 billion before the opening bell. Big Lots shares fell 5% to $41.45 in after-hours trading Thursday.\nDiDi Global Inc. (NYSE:DIDI) said that its board of directors had authorized the company to initiate procedures to delist the company’s shares from the New York Stock Exchange. The company, however, announced plans to pursue a listing of its class A ordinary shares on the Main Board of the Hong Kong Stock Exchange. DiDi Global shares jumped 9.5% to $8.54 in premarket trading Friday.\nAnalysts are expecting Hibbett, Inc. (NASDAQ:HIBB) to have earned $1.57 per share on revenue of $360.63 million for the latest quarter. The company will release earnings before the markets open. Hibbett shares rose 0.3% to $72.35 in after-hours trading Thursday.\n\n\nTesla Inc (NASDAQ:TSLA) Elon Musk sold another 934,091 shares worth around $1.01 billion in order to fulfill his tax obligations, as per filings made with the U.S. Securities And Exchange Commission Thursday. Musk also exercised options to purchase 2.1 million shares of the automaker at $6.24, as per one of the filings. In late November, the company’s CEO had sold $1 billion worth of Tesla shares. Tesla shares rose 0.3% to $1,088 in premarket tradingFriday.\nUlta Beauty, Inc. (NASDAQ:ULTA) reported better-than-expected results for its third quarter and raised its FY21 forecast. Ulta Beauty shares climbed 5.2% to $403.50 in the after-hours trading Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":2056,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603497233,"gmtCreate":1638437025726,"gmtModify":1638437670837,"author":{"id":"4099622722860440","authorId":"4099622722860440","name":"LiliMe","avatar":"https://static.tigerbbs.com/4202d921353cc8edc625e395870b44a6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099622722860440","authorIdStr":"4099622722860440"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603497233","repostId":"1120605182","repostType":4,"repost":{"id":"1120605182","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1638365714,"share":"https://www.laohu8.com/m/news/1120605182?lang=&edition=full","pubTime":"2021-12-01 21:35","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1120605182","media":"Benzinga","summary":"Morgan Stanley boosted Zscaler, Inc. price target from $275 to $330. Zscaler shares rose 7.1% to $37","content":"<ul>\n <li>Morgan Stanley boosted&nbsp;<b>Zscaler, Inc.</b>&nbsp;price target from $275 to $330. Zscaler shares rose 7.1% to $371.50 in pre-market trading.</li>\n <li>Citigroup boosted&nbsp;<b>Applied Materials, Inc.</b>&nbsp;price target from $160 to $175. Applied Materials shares rose 1.9% to $150.00 in pre-market trading.</li>\n <li>Goldman Sachs cut the price target on&nbsp;<b>TG Therapeutics, Inc.</b>&nbsp;from $26 to $13. TG Therapeutics shares fell 5.3% to $14.40 in pre-market trading.</li>\n <li>Wells Fargo boosted the price target for&nbsp;<b>Ambarella, Inc.</b>&nbsp;from $115 to $185. Ambarella shares jumped 16.4% to $208.90 in pre-market trading.</li>\n <li>Barclays cut&nbsp;<b>Sigilon Therapeutics, Inc.</b>&nbsp;price target from $16 to $7. Sigilon Therapeutics shares fell 0.3% to close at $3.76 on Tuesday.</li>\n <li>Credit Suisse lifted the price target on&nbsp;<b>GLOBALFOUNDRIES Inc.</b>&nbsp;from $75 to $80. GLOBALFOUNDRIES shares rose 3.3% to $71.50 in pre-market trading.</li>\n <li>DA Davidson raised&nbsp;<b>Helen of Troy Limited</b>&nbsp;price target from $254 to $266. Helen of Troy shares fell 2.3% to close at $240.50 on Tuesday.</li>\n <li>Jefferies lifted&nbsp;<b>ImmunoGen, Inc.</b>&nbsp;price target from $7 to $12. ImmunoGen shares fell 3.6% to $5.95 pre-market trading.</li>\n <li>Susquehanna raised the price target on&nbsp;<b>NetApp, Inc.</b>&nbsp;from $100 to $105. NetApp shares rose 1.4% to $90.11 in pre-market trading.</li>\n <li>Truist Securities boosted the price target for&nbsp;<b>Salesforce.com, inc.</b>&nbsp;from $315 to $330. salesforce.com shares fell 6.5% to $266.40 in pre-market trading.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-01 21:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Morgan Stanley boosted&nbsp;<b>Zscaler, Inc.</b>&nbsp;price target from $275 to $330. Zscaler shares rose 7.1% to $371.50 in pre-market trading.</li>\n <li>Citigroup boosted&nbsp;<b>Applied Materials, Inc.</b>&nbsp;price target from $160 to $175. Applied Materials shares rose 1.9% to $150.00 in pre-market trading.</li>\n <li>Goldman Sachs cut the price target on&nbsp;<b>TG Therapeutics, Inc.</b>&nbsp;from $26 to $13. TG Therapeutics shares fell 5.3% to $14.40 in pre-market trading.</li>\n <li>Wells Fargo boosted the price target for&nbsp;<b>Ambarella, Inc.</b>&nbsp;from $115 to $185. Ambarella shares jumped 16.4% to $208.90 in pre-market trading.</li>\n <li>Barclays cut&nbsp;<b>Sigilon Therapeutics, Inc.</b>&nbsp;price target from $16 to $7. Sigilon Therapeutics shares fell 0.3% to close at $3.76 on Tuesday.</li>\n <li>Credit Suisse lifted the price target on&nbsp;<b>GLOBALFOUNDRIES Inc.</b>&nbsp;from $75 to $80. GLOBALFOUNDRIES shares rose 3.3% to $71.50 in pre-market trading.</li>\n <li>DA Davidson raised&nbsp;<b>Helen of Troy Limited</b>&nbsp;price target from $254 to $266. Helen of Troy shares fell 2.3% to close at $240.50 on Tuesday.</li>\n <li>Jefferies lifted&nbsp;<b>ImmunoGen, Inc.</b>&nbsp;price target from $7 to $12. ImmunoGen shares fell 3.6% to $5.95 pre-market trading.</li>\n <li>Susquehanna raised the price target on&nbsp;<b>NetApp, Inc.</b>&nbsp;from $100 to $105. NetApp shares rose 1.4% to $90.11 in pre-market trading.</li>\n <li>Truist Securities boosted the price target for&nbsp;<b>Salesforce.com, inc.</b>&nbsp;from $315 to $330. salesforce.com shares fell 6.5% to $266.40 in pre-market trading.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GFS":"GLOBALFOUNDRIES Inc.","SGTX":"Sigilon Therapeutics, Inc.","CRM":"赛富时","NTAP":"美国网存","AMBA":"安霸","TGTX":"TG Therapeutics Inc.","ZS":"Zscaler Inc.","HELE":"海伦特洛伊家电","AMAT":"应用材料","IMGN":"ImmunoGen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120605182","content_text":"Morgan Stanley boosted Zscaler, Inc. price target from $275 to $330. Zscaler shares rose 7.1% to $371.50 in pre-market trading.\nCitigroup boosted Applied Materials, Inc. price target from $160 to $175. Applied Materials shares rose 1.9% to $150.00 in pre-market trading.\nGoldman Sachs cut the price target on TG Therapeutics, Inc. from $26 to $13. TG Therapeutics shares fell 5.3% to $14.40 in pre-market trading.\nWells Fargo boosted the price target for Ambarella, Inc. from $115 to $185. Ambarella shares jumped 16.4% to $208.90 in pre-market trading.\nBarclays cut Sigilon Therapeutics, Inc. price target from $16 to $7. Sigilon Therapeutics shares fell 0.3% to close at $3.76 on Tuesday.\nCredit Suisse lifted the price target on GLOBALFOUNDRIES Inc. from $75 to $80. GLOBALFOUNDRIES shares rose 3.3% to $71.50 in pre-market trading.\nDA Davidson raised Helen of Troy Limited price target from $254 to $266. Helen of Troy shares fell 2.3% to close at $240.50 on Tuesday.\nJefferies lifted ImmunoGen, Inc. price target from $7 to $12. ImmunoGen shares fell 3.6% to $5.95 pre-market trading.\nSusquehanna raised the price target on NetApp, Inc. from $100 to $105. NetApp shares rose 1.4% to $90.11 in pre-market trading.\nTruist Securities boosted the price target for Salesforce.com, inc. from $315 to $330. salesforce.com shares fell 6.5% to $266.40 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603497394,"gmtCreate":1638437002451,"gmtModify":1638437240940,"author":{"id":"4099622722860440","authorId":"4099622722860440","name":"LiliMe","avatar":"https://static.tigerbbs.com/4202d921353cc8edc625e395870b44a6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099622722860440","authorIdStr":"4099622722860440"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603497394","repostId":"1120605182","repostType":4,"repost":{"id":"1120605182","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1638365714,"share":"https://www.laohu8.com/m/news/1120605182?lang=&edition=full","pubTime":"2021-12-01 21:35","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1120605182","media":"Benzinga","summary":"Morgan Stanley boosted Zscaler, Inc. price target from $275 to $330. Zscaler shares rose 7.1% to $37","content":"<ul>\n <li>Morgan Stanley boosted&nbsp;<b>Zscaler, Inc.</b>&nbsp;price target from $275 to $330. Zscaler shares rose 7.1% to $371.50 in pre-market trading.</li>\n <li>Citigroup boosted&nbsp;<b>Applied Materials, Inc.</b>&nbsp;price target from $160 to $175. Applied Materials shares rose 1.9% to $150.00 in pre-market trading.</li>\n <li>Goldman Sachs cut the price target on&nbsp;<b>TG Therapeutics, Inc.</b>&nbsp;from $26 to $13. TG Therapeutics shares fell 5.3% to $14.40 in pre-market trading.</li>\n <li>Wells Fargo boosted the price target for&nbsp;<b>Ambarella, Inc.</b>&nbsp;from $115 to $185. Ambarella shares jumped 16.4% to $208.90 in pre-market trading.</li>\n <li>Barclays cut&nbsp;<b>Sigilon Therapeutics, Inc.</b>&nbsp;price target from $16 to $7. Sigilon Therapeutics shares fell 0.3% to close at $3.76 on Tuesday.</li>\n <li>Credit Suisse lifted the price target on&nbsp;<b>GLOBALFOUNDRIES Inc.</b>&nbsp;from $75 to $80. GLOBALFOUNDRIES shares rose 3.3% to $71.50 in pre-market trading.</li>\n <li>DA Davidson raised&nbsp;<b>Helen of Troy Limited</b>&nbsp;price target from $254 to $266. Helen of Troy shares fell 2.3% to close at $240.50 on Tuesday.</li>\n <li>Jefferies lifted&nbsp;<b>ImmunoGen, Inc.</b>&nbsp;price target from $7 to $12. ImmunoGen shares fell 3.6% to $5.95 pre-market trading.</li>\n <li>Susquehanna raised the price target on&nbsp;<b>NetApp, Inc.</b>&nbsp;from $100 to $105. NetApp shares rose 1.4% to $90.11 in pre-market trading.</li>\n <li>Truist Securities boosted the price target for&nbsp;<b>Salesforce.com, inc.</b>&nbsp;from $315 to $330. salesforce.com shares fell 6.5% to $266.40 in pre-market trading.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-01 21:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Morgan Stanley boosted&nbsp;<b>Zscaler, Inc.</b>&nbsp;price target from $275 to $330. Zscaler shares rose 7.1% to $371.50 in pre-market trading.</li>\n <li>Citigroup boosted&nbsp;<b>Applied Materials, Inc.</b>&nbsp;price target from $160 to $175. Applied Materials shares rose 1.9% to $150.00 in pre-market trading.</li>\n <li>Goldman Sachs cut the price target on&nbsp;<b>TG Therapeutics, Inc.</b>&nbsp;from $26 to $13. TG Therapeutics shares fell 5.3% to $14.40 in pre-market trading.</li>\n <li>Wells Fargo boosted the price target for&nbsp;<b>Ambarella, Inc.</b>&nbsp;from $115 to $185. Ambarella shares jumped 16.4% to $208.90 in pre-market trading.</li>\n <li>Barclays cut&nbsp;<b>Sigilon Therapeutics, Inc.</b>&nbsp;price target from $16 to $7. Sigilon Therapeutics shares fell 0.3% to close at $3.76 on Tuesday.</li>\n <li>Credit Suisse lifted the price target on&nbsp;<b>GLOBALFOUNDRIES Inc.</b>&nbsp;from $75 to $80. GLOBALFOUNDRIES shares rose 3.3% to $71.50 in pre-market trading.</li>\n <li>DA Davidson raised&nbsp;<b>Helen of Troy Limited</b>&nbsp;price target from $254 to $266. Helen of Troy shares fell 2.3% to close at $240.50 on Tuesday.</li>\n <li>Jefferies lifted&nbsp;<b>ImmunoGen, Inc.</b>&nbsp;price target from $7 to $12. ImmunoGen shares fell 3.6% to $5.95 pre-market trading.</li>\n <li>Susquehanna raised the price target on&nbsp;<b>NetApp, Inc.</b>&nbsp;from $100 to $105. NetApp shares rose 1.4% to $90.11 in pre-market trading.</li>\n <li>Truist Securities boosted the price target for&nbsp;<b>Salesforce.com, inc.</b>&nbsp;from $315 to $330. salesforce.com shares fell 6.5% to $266.40 in pre-market trading.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GFS":"GLOBALFOUNDRIES Inc.","SGTX":"Sigilon Therapeutics, Inc.","CRM":"赛富时","NTAP":"美国网存","AMBA":"安霸","TGTX":"TG Therapeutics Inc.","ZS":"Zscaler Inc.","HELE":"海伦特洛伊家电","AMAT":"应用材料","IMGN":"ImmunoGen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120605182","content_text":"Morgan Stanley boosted Zscaler, Inc. price target from $275 to $330. Zscaler shares rose 7.1% to $371.50 in pre-market trading.\nCitigroup boosted Applied Materials, Inc. price target from $160 to $175. Applied Materials shares rose 1.9% to $150.00 in pre-market trading.\nGoldman Sachs cut the price target on TG Therapeutics, Inc. from $26 to $13. TG Therapeutics shares fell 5.3% to $14.40 in pre-market trading.\nWells Fargo boosted the price target for Ambarella, Inc. from $115 to $185. Ambarella shares jumped 16.4% to $208.90 in pre-market trading.\nBarclays cut Sigilon Therapeutics, Inc. price target from $16 to $7. Sigilon Therapeutics shares fell 0.3% to close at $3.76 on Tuesday.\nCredit Suisse lifted the price target on GLOBALFOUNDRIES Inc. from $75 to $80. GLOBALFOUNDRIES shares rose 3.3% to $71.50 in pre-market trading.\nDA Davidson raised Helen of Troy Limited price target from $254 to $266. Helen of Troy shares fell 2.3% to close at $240.50 on Tuesday.\nJefferies lifted ImmunoGen, Inc. price target from $7 to $12. ImmunoGen shares fell 3.6% to $5.95 pre-market trading.\nSusquehanna raised the price target on NetApp, Inc. from $100 to $105. NetApp shares rose 1.4% to $90.11 in pre-market trading.\nTruist Securities boosted the price target for Salesforce.com, inc. from $315 to $330. salesforce.com shares fell 6.5% to $266.40 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1353,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603016622,"gmtCreate":1638338084779,"gmtModify":1638338084779,"author":{"id":"4099622722860440","authorId":"4099622722860440","name":"LiliMe","avatar":"https://static.tigerbbs.com/4202d921353cc8edc625e395870b44a6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099622722860440","authorIdStr":"4099622722860440"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603016622","repostId":"1190156196","repostType":4,"repost":{"id":"1190156196","kind":"news","pubTimestamp":1638242388,"share":"https://www.laohu8.com/m/news/1190156196?lang=&edition=full","pubTime":"2021-11-30 11:19","market":"us","language":"en","title":"5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1190156196","media":"InvestorPlace","summary":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race","content":"<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537aabc5fd6c7ca4f614ce1b37dc0a75\" tg-width=\"1024\" tg-height=\"576\" width=\"100%\" height=\"auto\"><span>Source: Shutterstock</span></p>\n<p>As Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?</p>\n<p>Investors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.</p>\n<p>While&nbsp;<b>Pfizer’s</b>(NYSE:<b><u>PFE</u></b>)&nbsp;success in&nbsp;producing&nbsp;a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.</p>\n<p>Many vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.</p>\n<ul>\n <li><b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>)</li>\n <li><b>Pfizer</b>(NYSE:<b><u>PFE</u></b>)</li>\n <li><b>BioNTech</b>&nbsp;(NASDAQ:<b><u>BNTX</u></b>)</li>\n <li><b>Johnson &amp; Johnson</b>(NYSE:<b><u>JNJ</u></b>)</li>\n <li><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>)</li>\n</ul>\n<p><b>Moderna (MRNA)</b></p>\n<p>Moderna was one of the first companies to have its executive team discuss address the omicron variant.</p>\n<p>On Sunday, CMO Paul Burton spoke to<i>BBC’s</i>Andrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketo<i>CNBC’s</i>“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.</p>\n<p>Bancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.</p>\n<p>This talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.</p>\n<p>While&nbsp;the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p>\n<p>\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p>\n<p>\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p>\n<p><b>Pfizer (PFE)</b></p>\n<p>No pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one&nbsp;<i>InvestorPlace</i>&nbsp;contributorfor CEO of the year.</p>\n<p>The industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.</p>\n<p>Clinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.</p>\n<p>While Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.</p>\n<p>It is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.</p>\n<p><b>BioNTech (BNTX)</b></p>\n<p>Pfizer’s original vaccine partner isn’t missing a beat, either.</p>\n<p>The German biotech innovatortold<i>Business Insider</i>that it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.</p>\n<p>Like its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.</p>\n<p>Like other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,<i>InvestorPlace</i>&nbsp;analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.</p>\n<p><b>Johnson &amp; Johnson (JNJ)</b></p>\n<p>Like its competitors, Johnson &amp; Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”</p>\n<p>Mathai Mammen, global head of research and development at J&amp;J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.</p>\n<p>Mammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.</p>\n<p><b>Novavax (NVAX)</b></p>\n<p>A later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.</p>\n<p>However, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”</p>\n<p>While Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.</p>\n<p>As&nbsp;<i>InvestorPlace</i>&nbsp;Assistant News Writer&nbsp;Eddie Pan&nbsp;reported&nbsp;this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 11:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis ...</p>\n\n<a href=\"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","BNTX":"BioNTech SE","JNJ":"强生","MRNA":"Moderna, Inc."},"source_url":"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190156196","content_text":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?\nInvestors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.\nWhile Pfizer’s(NYSE:PFE) success in producing a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.\nMany vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.\n\nModerna(NASDAQ:MRNA)\nPfizer(NYSE:PFE)\nBioNTech (NASDAQ:BNTX)\nJohnson & Johnson(NYSE:JNJ)\nNovavax(NASDAQ:NVAX)\n\nModerna (MRNA)\nModerna was one of the first companies to have its executive team discuss address the omicron variant.\nOn Sunday, CMO Paul Burton spoke toBBC’sAndrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketoCNBC’s“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.\nBancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.\nThis talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.\nWhile the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nPfizer (PFE)\nNo pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one InvestorPlace contributorfor CEO of the year.\nThe industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.\nClinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.\nWhile Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.\nIt is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.\nBioNTech (BNTX)\nPfizer’s original vaccine partner isn’t missing a beat, either.\nThe German biotech innovatortoldBusiness Insiderthat it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.\nLike its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.\nLike other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,InvestorPlace analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.\nJohnson & Johnson (JNJ)\nLike its competitors, Johnson & Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”\nMathai Mammen, global head of research and development at J&J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.\nMammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.\nNovavax (NVAX)\nA later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.\nHowever, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”\nWhile Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.\nAs InvestorPlace Assistant News Writer Eddie Pan reported this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603016147,"gmtCreate":1638338057130,"gmtModify":1638338057130,"author":{"id":"4099622722860440","authorId":"4099622722860440","name":"LiliMe","avatar":"https://static.tigerbbs.com/4202d921353cc8edc625e395870b44a6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099622722860440","authorIdStr":"4099622722860440"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603016147","repostId":"1129131439","repostType":4,"repost":{"id":"1129131439","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638285839,"share":"https://www.laohu8.com/m/news/1129131439?lang=&edition=full","pubTime":"2021-11-30 23:23","market":"us","language":"en","title":"Gold and silver stocks  jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1129131439","media":"Tiger Newspress","summary":"Gold and silver stocks jumped in morning trading.","content":"<p>Gold and silver stocks jumped in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/02c176526990e689ddfc9f7ffa90e282\" tg-width=\"396\" tg-height=\"657\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd1aad69af976f6877e0d77ba4618b6e\" tg-width=\"399\" tg-height=\"301\" referrerpolicy=\"no-referrer\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gold and silver stocks  jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGold and silver stocks  jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-30 23:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gold and silver stocks jumped in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/02c176526990e689ddfc9f7ffa90e282\" tg-width=\"396\" tg-height=\"657\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd1aad69af976f6877e0d77ba4618b6e\" tg-width=\"399\" tg-height=\"301\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AG":"First Majestic Silver Corporation","MAG":"MAG银矿","FSM":"Fortuna Silver Mines Inc","GFI":"金田","PAAS":"泛美白银","HMY":"哈莫尼黄金","KGC":"金罗斯黄金","EXK":"Endeavour Silver","NEM":"纽曼矿业","AEM":"伊格尔矿业","HL":"赫克拉矿业","GOLD":"巴里克黄金","AU":"AngloGold Ashanti Ltd ADS","CDE":"科尔黛伦矿业","USAU":"美国黄金公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129131439","content_text":"Gold and silver stocks jumped in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1391,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600242226,"gmtCreate":1638164595269,"gmtModify":1638164595269,"author":{"id":"4099622722860440","authorId":"4099622722860440","name":"LiliMe","avatar":"https://static.tigerbbs.com/4202d921353cc8edc625e395870b44a6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099622722860440","authorIdStr":"4099622722860440"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600242226","repostId":"1119853738","repostType":4,"repost":{"id":"1119853738","kind":"news","pubTimestamp":1638153494,"share":"https://www.laohu8.com/m/news/1119853738?lang=&edition=full","pubTime":"2021-11-29 10:38","market":"us","language":"en","title":"Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1119853738","media":"Motley Fool","summary":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday","content":"<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.</p>\n<p>While there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.</p>\n<p>How should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers&nbsp;<b>Moderna</b>(NASDAQ:MRNA),<b>Pfizer</b>(NYSE:PFE), and&nbsp;<b>Novavax</b>(NASDAQ:NVAX)&nbsp;all&nbsp;vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.</p>\n<p>The pandemic's latest twist makes these three stocks screaming buys</p>\n<p>Moderna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.</p>\n<p>Pfizer, for its part, said that its&nbsp;<b>BioNTech</b>-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.</p>\n<p>Why are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.</p>\n<p>While Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.</p>\n<p>On the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have&nbsp;dipped in the back half of 2021&nbsp;in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.</p>\n<p>What's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.</p>\n<p>In short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Pfizer, and Novavax Are Must-Own Stocks This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Pfizer, and Novavax Are Must-Own Stocks This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/11/28/moderna-pfizer-and-novavax-are-must-own-stocks-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119853738","content_text":"The newly emerged omicron coronavirus variant sent shockwaves through U.S. stock markets last Friday. Omicron has the world on edge because of its unique combination of mutations that might significantly reduce the effectiveness of first-generation COVID-19 vaccines.\nWhile there simply isn't enough data to draw any firm conclusions about the seriousness of the omicron variant yet, politicians across the world were quick to react by imposing travel bans and restrictions on several African nations over the weekend. These rapid-fire travel restrictions make it abundantly clear that the global pandemic -- and its effects on the world economy -- are far from over.\nHow should investors protect their portfolios from this latest threat to global supply chains, international travel, and public health? The answer appears to be simple enough: vaccine stocks. On Black Friday, shares of the top COVID-19 vaccine developers Moderna(NASDAQ:MRNA),Pfizer(NYSE:PFE), and Novavax(NASDAQ:NVAX) all vaulted higher. Here's why these threebiopharmaceutical stocksought to continue to their march northward next week and beyond.\nThe pandemic's latest twist makes these three stocks screaming buys\nModerna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.\nPfizer, for its part, said that its BioNTech-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.\nWhy are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.\nWhile Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022.\nOn the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.\nWhat's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.\nIn short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1706,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}